OakChart

Geron Corp

GERNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:01 AM ET

0.9955+0.0213 (2.19%)
2026-11-11 17:01 CET
Market cap
627.62 USD m
Revenue, TTM
217.52 USD m
Net income, TTM
-50.12 USD m
Free cash flow, TTM
-91.16 USD m
EPS diluted, TTM
-0.07
P/E
-
Compare

Price

GERN against its 20, 50 and 200-day averages
2050200beatmiss
0.801.001.201.401.6040.9M81.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GERNclose 1.0020-day 1.0650-day 1.21200-day 1.411.0052w low

50.4% under the 52-week high of 2.01 on 19 Feb 2026. 52-week low 0.84 on 28 Oct 2026. Last 15 sessions, 41.7% high to low

Profile

GERN
52-week range, 13% of the way up
0.842.01

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

IndexRUT
Employees258
IPOJul 31, 1996
Beta0.60
ATR, 14d0.08
Rel volume0.29
Short float10.54%
Insider own1.43%
Inst own73.60%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap641.34M
Enterprise Value603.24M
Income-50.12M
Sales217.52M
Book/sh0.35
Cash/sh0.45
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees258
IPOJul 31, 1996

Ratios

P/E-
Forward P/E13.83
PEG-
P/S2.95
P/B2.83
P/C2.22
P/FCF-
EV/EBITDA-
EV/Sales2.77
Quick Ratio4.61
Current Ratio6.31
Debt/Eq1.10
LT Debt/Eq1.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.07
EPS next Y0.07
EPS next Q0.00
EPS this Y78.46%
EPS next Y357.14%
EPS next 5Y-
EPS past 3/5Y30.48% 14.78%
Sales past 3/5Y575.71% 273.49%
EPS Y/Y TTM37.60%
Sales Y/Y TTM18.60%
EPS Q/Q107.25%
Sales Q/Q27.45%
EarningsNov 04 BMO
EPS/Sales Surpr.100.00% -0.28%

Ownership

Insider Own1.43%
Insider Trans0.00%
Inst Own73.60%
Inst Trans-1.60%
ROA-9.16%
ROE-21.08%
ROIC-11.07%
Gross Margin94.50%
Oper. Margin-8.25%
Profit Margin-23.04%
SMA20-6.10%
SMA50-17.41%
SMA200-29.42%
Trades-

Technical

Shs Outstand644.24M
Shs Float635.02M
Short Float10.54%
Short Ratio5.50
Short Interest66.95M
52W High2.01 -50.47%
52W Low0.84 18.51%
Volatility9.73% 7.68%
ATR (14)0.08
RSI (14)41.95
Beta0.60
Rel Volume0.29
Avg Volume12.16M
Volume964,690

Performance

Perf Week-7.82%
Perf Month-17.04%
Perf Quarter-35.15%
Perf Half Y-29.40%
Perf YTD-24.58%
Perf Year-20.36%
Perf 3Y-42.79%
Perf 5Y-34.93%
Perf 10Y-54.75%
Recom1.40
Target Price3.50
Prev Close0.97
Price1.00
Change %2.19%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 10, 2025ResumedGGoldmanSell$1+0.5%
May 08, 2025DowngradeBScotiabankSector Outperform → Sector Perform$1.50+50.7%
Feb 27, 2025DowngradeRB. Riley SecuritiesBuy → Neutral$3.50 → $2+100.9%
Feb 26, 2025DowngradeHH.C. WainwrightBuy → Neutral
Nov 05, 2024InitiatedHH.C. WainwrightBuy$8+703.6%
Oct 16, 2024InitiatedBScotiabankSector Outperform
Sep 09, 2024InitiatedLLeerink PartnersOutperform$7+603.2%
Apr 30, 2024DowngradeRRobert W. BairdOutperform → Neutral$4.50+352.0%
Apr 29, 2024InitiatedTTD CowenBuy$10+904.5%
Mar 15, 2024ReiteratedNNeedhamBuy$4 → $5+402.3%

Peers

Mkt cap
TickerCompanyMkt cap
AGIOAgios Pharmaceuticals Inc1.92B
DMRADamora Therapeutics Inc1.53B
RIGLRigel Pharmaceuticals832.37M
INCYIncyte Corp24.61B
BMYBristol-Myers Squibb Co125.65B
KROSKeros Therapeutics Inc186.44M
SNDXSyndax Pharmaceuticals Inc864.06M
IRONDisc Medicine Inc3.88B
AAPGAscentage Pharma Group International ADR1.41B
GLUEMonte Rosa Therapeutics Inc879.71M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Option Exercise0.0027,500027,500Feb 19 06:10 PM
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Sale1.949,85519,11917,645Feb 19 06:10 PM
JAMES ZIEGLEROfficerDec 15 '25Proposed Sale1.3720,00027,400Dec 15 05:33 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
BBPVirtus Biotech ETFAUM: 135.69M

News

latest 14 of 206
  • Geron Turns Profitable As RYTELO Demand Accelerates, But The Myelofibrosis Failure Leaves A One-Product Story (Earnings Whispers) +16.13%
  • Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO (imetelstat) at ASH 2026 (GlobeNewswire)
  • Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Geron Corporation to Participate in the Stifel 2026 Healthcare Conference (GlobeNewswire)
  • Geron winds down Phase III rare blood cancer trial after muted efficacy (Clinical Trials Arena) -5.47%
  • Loading…
  • Geron stock tumbles after halting Phase 3 trial (Investing.com) -15.78%
  • Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis (GlobeNewswire)
  • Geron's Rytelo Ramp Faces A Math Test As Stock Slides Toward Its Lows (Earnings Whispers)
  • Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire) -6.45%
  • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia (GlobeNewswire)
  • Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.000-0.0080.00060.1960.365
2026Q22026-08-05-0.020-0.009-0.02557.4855.305
2026Q12026-05-06-0.010-0.020-0.00551.8450.596
2025Q42026-02-25-0.050-0.030-0.04748.0250.426
2025Q32025-11-05-0.030-0.032-0.02847.2353.238
2025Q22025-08-06-0.020-0.029-0.02549.0447.2810
2025Q12025-05-07-0.030-0.036-0.03039.6048.299
2024Q42025-02-26-0.040-0.025-0.03847.5461.849
2024Q32024-11-07-0.040-0.084-0.04028.2718.9710
2024Q22024-08-08-0.100-0.103-0.1030.880.347
2024Q12024-05-02-0.090-0.096-0.0920.300.037
2023Q42024-02-28-0.090-0.105-0.0870.020.086
2023Q32023-11-02-0.080-0.097-0.0770.160.066
2023Q22023-08-03-0.090-0.083-0.0900.030.076
2023Q12023-05-11-0.070-0.100-0.0700.020.076
2022Q42023-03-16-0.100-0.123-0.1050.100.126

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.360-0.420-0.3610.460.36
2020FY-0.280-0.262-0.2790.250.24
2021FY-0.350-0.336-0.3541.390.42
2022FY-0.370-0.383-0.3730.600.60
2023FY-0.320-0.343-0.3230.240.29
2024FY-0.270-0.252-0.27076.9991.14
2025FY-0.130-0.100-0.130183.88186.29
2026FY--0.028--235.32
2027FY-0.072--320.51
2028FY-0.223--490.88
2029FY-0.380--624.94
2030FY-0.503--760.46

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0652165.5064.5066.64
2026Q4S2026-11-0452165.4964.5066.64
2026Q4S2026-10-2750165.6963.9968.03
2026Q4S2026-10-2050165.6963.9968.03
2026Q4S2026-10-1950066.2763.9968.21
2026Q4S2026-08-1251266.2763.9968.21
2026Q4S2026-08-0551266.2763.9968.20
2026Q4S2026-07-2250066.9465.0070.56
2026Q4S2026-07-2150067.0265.0070.56
2026Q4S2026-07-2060066.8365.0070.56
2026Q4S2026-05-1163166.8365.0070.56
2026Q4S2026-05-0663166.8465.0070.60
2026Q4S2026-04-2661066.2064.6568.60
2026Q4S2026-04-2261166.2064.6568.60

Estimate history

EPS, annual-0.175-0.153-0.361-0.279-0.354-0.373-0.323-0.27-0.125-0.075
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.04-0.038-0.03-0.025-0.028-0.047-0.005-0.0250.002
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.0651.0660.460.2531.3930.5960.23776.994183.881217.52
Period201720182019202020212022202320242025TTM
Sales, quarterly28.27147.53839.60349.03647.22748.01551.83757.4860.19
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual159.877186.393199.815310.567323.732390.263544.912606.388639.856644.238
Period201720182019202020212022202320242025MRQ
Shares, quarterly603.102606.388636.918637.85638.355639.856641.033642.47644.238
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue217.52183.8876.990.240.601.390.250.461.07
Cost of Goods Sold Incl. D&A11.964.751.261.030.870.78---
Gross Profit205.56179.1475.74-0.80-0.270.61---
Selling, General and Administrative Excl. Other217.18230.69249.47193.15138.28114.6176.2372.1932.08
Research and Development65.5371.43103.74125.0595.5285.7351.4952.0713.43
Other Operating Expense6.330.000.000.000.000.000.000.000.00
Operating Income-17.95-51.55-173.73-193.94-138.55-114.00-76.91-72.50-31.07
Interest Expense28.8032.6618.508.316.883.740.76-0.00
Unusual Expense16.4117.031.710.000.000.00-0.060.200.54
Net Income Before Taxes-50.12-83.50-174.57-184.13-141.90-116.11-75.62-68.55-27.02
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-50.12-83.50-174.57-184.13-141.90-116.11-75.62-68.55-27.02
Net Income From Continuing Operations-50.12-83.50-174.57-184.13-141.90-116.11-75.62-68.55-27.02
Net Income-50.12-83.50-174.57-184.13-141.90-116.11-75.62-68.55-27.02
EPS (Recurring)-0.06-0.11-0.27-0.32-0.37-0.35-0.28-0.36-0.15
EPS (Basic, Before Extraordinaries)-0.07-0.13-0.27-0.32-0.37-0.35-0.28-0.36-0.15
EPS (Diluted)-0.07-0.13-0.27-0.32-0.37-0.35-0.28-0.36-0.15
EBITDA-16.68-50.35-172.51-192.91-137.68-113.22-75.98-71.73-31.01
Non-Operating Income (Expense)13.0417.7419.3718.133.531.632.004.154.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense19.1925.4431.9314.638.008.086.896.086.37
Price To Sales Ratio3.814.7929.705,080.431,546.14286.941,706.02562.21165.58
Gross Margin94.5097.4298.37-335.86-45.6443.79---
Operating Margin-8.25-28.04-225.64-81,832.91-23,246.64-8,183.70-30,400.40-15,761.96-2,914.92
Net Margin-23.04-45.41-226.73-77,690.72-23,808.89-8,335.39-29,888.14-14,901.74-2,534.43
Shares Outstanding644.24639.86606.39544.91390.26323.73310.57199.81186.39
Market Capitalization627.62627.622,139.931,145.87922.59392.78493.65271.70186.35

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue60.1957.4851.8448.0247.2349.0439.6047.54
Cost of Goods Sold Incl. D&A6.052.911.691.311.351.501.510.78
Gross Profit54.1454.5750.1546.7145.8747.5438.0946.76
Selling, General and Administrative Excl. Other48.4160.8950.3857.5059.7659.9954.7966.80
Research and Development12.7122.0314.9615.8321.0721.7415.0823.43
Other Operating Expense0.006.330.000.000.000.000.000.00
Operating Income5.73-12.65-0.24-10.79-13.89-12.45-16.70-20.05
Interest Expense7.217.157.157.308.648.528.208.71
Unusual Expense-0.07-0.16-0.3917.030.000.000.001.71
Net Income Before Taxes1.35-16.68-3.64-31.14-18.43-16.38-19.84-25.35
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income1.35-16.68-3.64-31.14-18.43-16.38-19.84-25.35
Net Income From Continuing Operations1.35-16.68-3.64-31.14-18.43-16.38-19.84-25.35
Net Income1.35-16.68-3.64-31.14-18.43-16.38-19.84-25.35
EPS (Recurring)0.00-0.03-0.01-0.03-0.03-0.02-0.03-0.04
EPS (Basic, Before Extraordinaries)0.00-0.02-0.01-0.05-0.03-0.02-0.03-0.04
EPS (Diluted)0.00-0.02-0.01-0.05-0.03-0.02-0.03-0.04
EBITDA6.06-12.320.09-10.52-13.57-12.14-16.40-19.73
Non-Operating Income (Expense)2.762.963.353.984.104.595.075.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.804.934.904.556.746.747.417.54
Price To Sales Ratio3.814.205.094.794.985.719.1030.54
Gross Margin89.9594.9496.7497.2897.1396.9496.1898.35
Operating Margin9.52-22.01-0.46-22.47-29.40-25.40-42.18-42.17
Net Margin2.24-29.02-7.03-64.86-39.02-33.39-50.08-53.33
Shares Outstanding644.24642.47641.03639.86638.36637.85636.92606.39
Market Capitalization627.62821.15954.41842.63874.08898.051,012.682,139.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments359.80408.43334.81173.11184.09196.64139.59163.5694.95
Short Term Receivables39.2338.801.663.141.760.720.801.170.44
Inventories116.6438.710.000.000.000.000.000.000.00
Other Current Assets4.615.054.883.991.362.501.211.330.58
Total Current Assets520.27490.99341.35180.25187.21199.86141.61166.0695.97
Net Property, Plant & Equipment3.044.194.734.945.385.952.900.060.10
Total Investments and Advances41.2994.5243.300.0028.6563.7520.0419.1714.24
Intangible Assets---0.000.000.000.000.000.00
Deferred Tax Assets0.540.68-------
Other Assets5.954.084.705.394.801.170.960.000.00
Total Assets571.08594.46394.08190.57226.03270.73165.52185.28110.31
Short Term Debt Incl. Current Port. of LT Debt18.4521.3547.8421.870.900.880.350.000.00
Accounts Payable11.268.606.1610.196.696.921.180.980.50
Other Current Liabilities81.8458.3654.0744.6337.9323.1426.636.576.01
Total Current Liabilities111.5488.30108.0776.6945.5230.9428.167.556.52
Long Term Debt233.13225.1638.0633.8854.1028.842.200.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.540.68-------
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities345.21314.14146.13110.5899.6259.7830.367.556.52
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity225.87280.32247.9580.00126.42210.95135.16177.73103.80
Total Shareholders Equity225.87280.32247.9580.00126.42210.95135.16177.73103.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity225.87280.32247.9580.00126.42210.95135.16177.73103.80
Total Liabilities & Stockholders Equity571.08594.46394.08190.57226.03270.73165.52185.28110.31
Book Value Per Share0.350.460.460.200.390.680.680.950.65
Tangible Book Value Per Share0.350.460.460.200.390.680.680.950.65
Full-Time Employees2582291411076955461815
Price to Book Ratio2.777.303.948.533.122.342.011.052.65
Return on Assets-14.33-35.32-62.99-68.12-46.75-34.67-39.08-18.28-23.21
Return on Equity-32.99-66.09-112.29-137.49-68.84-43.70-43.82-19.19-24.69
Return on Invested Capital-18.19-34.54-64.38-124.60-64.32-31.53-49.91-15.20-26.89
Quick Ratio3.625.123.162.354.116.465.0321.9914.73
Current Ratio4.665.563.162.354.116.465.0321.9914.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-47.83-83.50-174.57-184.13-141.90-116.11-75.62-68.55-27.02
Depreciation1.271.201.221.030.870.780.940.780.06
Other Funds (Non Cash)54.3239.8023.149.298.639.267.654.826.19
Funds from Operations7.76-42.50-150.21-173.80-132.41-106.07-67.03-62.95-20.76
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-98.29-68.54-68.416.065.0310.520.3819.12-0.24
Cash from Operating Activities-90.53-111.04-218.62-167.74-127.38-95.56-66.65-43.83-21.01
Capital Expenditures-0.63-0.05-0.68-0.83-0.43-0.21-0.40-0.41-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments76.02107.30-105.32-179.4962.5072.15-104.9227.81-77.70
Purchase of Investments-325.09-304.42-476.93-475.59-258.01-177.43-313.20-153.47-188.37
Sale Or Maturity of Investments401.10411.72371.61296.10320.50249.59208.28181.28110.66
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities75.39107.25-106.00-180.3262.0771.95-105.3227.40-77.72
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.352.27174.81332.3287.2623.66144.4819.5092.97
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.352.27174.81332.3287.2623.66144.4819.5092.97
Proceedsfrom Stock Options6.732.27173.41226.4172.1020.39144.2619.3092.97
Issuance or Reduction of Debt, Net0.000.00159.5729.700.0024.8923.860.000.00
Change in Long Term Debt0.000.00159.5729.700.0024.8923.860.000.00
Issuance of Long Term Debt0.000.00246.1229.700.0024.8923.860.000.00
Reduction of Long Term Debt0.000.00-86.550.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00--0.000.00
Cash from Financing Activities6.352.27334.37362.0287.2648.56168.3519.5092.97
Exchange Rate Effect-0.130.09-0.01-0.030.02----
Net Change in Cash-8.92-1.449.7413.9321.9724.95-3.633.07-5.76
Free Cash Flow-91.16-111.09-219.30-168.57-127.81-95.76-67.05-44.24-21.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments288.37302.74314.29359.80382.41389.85
Short Term Receivables48.0153.5044.0939.2337.6639.36
Inventories126.60123.60133.29116.6495.4269.12
Other Current Assets5.766.506.864.616.867.26
Total Current Assets468.74486.34498.53520.27522.34505.60
Net Property, Plant & Equipment1.672.852.963.043.313.71
Total Investments and Advances51.0024.1226.6941.2939.0642.74
Deferred Tax Assets---0.54--
Other Assets5.705.705.945.952.673.15
Total Assets527.11519.01534.12571.08567.38555.20
Short Term Debt Incl. Current Port. of LT Debt24.1121.7020.4018.4520.2918.43
Accounts Payable15.468.8012.7211.2611.118.23
Other Current Liabilities34.6839.8240.4581.8456.3237.63
Total Current Liabilities74.2570.3373.57111.5487.7164.28
Long Term Debt226.16230.06231.44233.13230.96231.38
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.54--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities300.41300.39305.01345.21318.68295.67
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity226.69218.61229.11225.87248.71259.53
Total Shareholders Equity226.69218.61229.11225.87248.71259.53
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity226.69218.61229.11225.87248.71259.53
Total Liabilities & Stockholders Equity527.11519.01534.12571.08567.38555.20
Book Value Per Share0.350.340.360.350.390.41
Tangible Book Value Per Share0.350.340.360.350.390.41
Full-Time Employees---258--
Price to Book Ratio2.773.584.223.393.373.35
Return on Assets-9.16-13.01-12.69-14.72-15.80-17.52
Return on Equity-21.08-29.24-27.98-33.89-29.57-31.09
Return on Invested Capital0.30-3.72-0.79-6.79-3.84-3.34
Quick Ratio4.615.164.963.624.876.79
Current Ratio6.316.926.784.665.967.87

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income1.35-16.68-3.64-28.86-18.43-16.38
Depreciation0.340.330.330.280.310.31
Other Funds (Non Cash)13.3813.918.0418.996.867.23
Funds from Operations15.07-2.444.73-9.60-11.26-8.83
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.80-13.39-67.63-12.47-2.31-18.58
Cash from Operating Activities10.27-15.83-62.91-22.07-13.58-27.41
Capital Expenditures-0.15-0.22-0.250.000.090.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00-0.03
Purchase or Sale of Investments-5.768.5252.1121.1413.2620.48
Purchase of Investments-97.44-88.90-34.52-104.22-77.03-76.70
Sale Or Maturity of Investments91.6997.4286.63125.3690.2997.18
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.918.2951.8621.1413.3520.32
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.171.382.420.380.541.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.171.382.420.380.541.09
Proceedsfrom Stock Options2.171.380.912.270.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.171.382.420.380.541.09
Exchange Rate Effect0.02-0.10-0.04-0.010.070.00
Net Change in Cash6.54-6.25-8.66-0.550.39-6.01
Free Cash Flow10.11-16.05-63.16-22.07-13.49-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.54%67.0M635.0M11.58M
2026-10-1511.78%74.6M633.3M9.80M
2026-09-3011.67%73.9M633.3M10.27M
2026-09-1513.05%82.6M633.3M11.40M
2026-08-3113.44%85.1M633.3M11.48M
2026-08-1412.84%80.6M628.0M11.91M
2026-07-3112.22%76.8M628.4M12.70M
2026-07-1511.14%69.9M627.5M13.85M
2026-06-3012.78%80.2M627.5M15.91M
2026-06-1511.93%74.8M627.3M16.25M
2026-05-2911.44%71.8M627.4M17.19M
2026-05-1511.18%70.2M627.4M19.15M
2026-04-3012.43%75.7M609.0M18.59M
2026-04-1513.50%82.2M608.4M18.47M
2026-03-3112.61%76.7M607.8M16.20M
2026-03-1310.40%63.2M607.8M13.80M
2026-02-279.97%60.6M607.8M11.86M
2026-02-1310.74%65.0M605.7M9.59M
2026-01-309.62%58.5M607.4M8.90M
2026-01-1511.60%70.5M607.4M7.84M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.101.100.450.00011.000.000.901-0.0070.000
call1.000.050.100.051.6764800.000.550-0.0070.001
call1.500.000.050.052.9069670.000.236-0.0080.000
call2.000.000.050.053.77697.000.000.195-0.0080.000
call3.000.000.050.004.9790.000.000.165-0.0100.000
call4.000.000.050.005.7520.000.000.151-0.0110.000
put0.500.000.050.004.5200.000.00-0.103-0.0070.000
put1.000.000.150.102.3401101.00-0.450-0.0070.001
put1.500.101.100.5012.28011.000.00-0.763-0.0070.000
put2.000.601.600.0013.3910.000.00-0.805-0.0090.000
put3.001.552.550.0013.7530.000.00-0.836-0.0110.000
put4.002.403.400.0012.0390.000.00-0.850-0.0110.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-05SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-05-278-KCurrent report2026-05-20SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-08SCHEDULE 13G/ASEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-144Statement of changes in beneficial ownership of securities2026-04-13SEC
2026-04-143Initial statement of beneficial ownership of securities2026-04-13SEC
2026-04-07ARSAnnual report to security holders. 2025-12-31SEC
2026-04-07DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-07DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-20SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-03-264Statement of changes in beneficial ownership of securities2026-03-25SEC
2026-03-263Initial statement of beneficial ownership of securities2026-03-25SEC
2026-03-264Statement of changes in beneficial ownership of securities2026-03-25SEC
2026-03-263Initial statement of beneficial ownership of securities2026-03-25SEC
2026-03-268-KCurrent report2026-03-25SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020019.12K1
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.7.66%
RA CAPITAL MANAGEMENT, L.P.6.67%
Soleus Capital Management, L.P.6.67%
STATE STREET CORP5.59%
CITADEL ADVISORS LLC4.53%
VANGUARD CAPITAL MANAGEMENT LLC4.25%
Nantahala Capital Management, LLC3.81%
Clearbridge Investments, LLC3.06%
Eversept Partners, LP2.92%
GOLDMAN SACHS GROUP INC2.59%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.40%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.19%
iShares Russell 2000 ETF2.26%
VANGUARD EXPLORER FUND2.02%
ClearBridge Small Cap Growth Fund0.98%
VANGUARD EXTENDED MARKET INDEX FUND0.95%
Fidelity Small Cap Index Fund0.95%
Select Biotechnology Portfolio0.85%
iShares Russell 2000 Growth ETF0.80%
iShares Biotechnology ETF0.69%

OakChart. GERN. Cached 15 minutes.